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1. Introduction 
Renal transplantation has become the treatment of choice for patients with end-stage renal 
disease (ESRD) resulting from a variety of causes. The short-term patient and graft outcomes 
have improved markedly over the recent years (Hariharan et al., 2000). Renal transplant 
recipients are subject to all those diseases which affect the general population. In addition, 
like all other allograft recipients, renal transplant recipients are also susceptible to a variety 
of unique pathological lesions not seen in the non-transplant population. These lesions may 
involve the transplanted organ or other native organs/systems of the transplant recipients. 
The focus of this chapter will be on the major pathological processes affecting the kidney 
allograft itself and are diagnosed on renal allograft biopsy. In this chapter we will present a 
brief but comprehensive overview of the pathology of the renal allograft seen on allograft 
biopsies supplemented by representative pictures.  
2. Role of renal allograft biopsy in the management of renal transplant 
patients 
The renal allograft biopsy plays an important role in the diagnosis and management of 
causes of renal allograft dysfunction (Al-Awwa et al., 1998; Colvin,1996; Gaber, 1998; 
Mazzali et al., 1999; Matas et al., 1983; Matas et al., 1985; Parfrey et al., 1984). Regarding 
biopsy indications, it is befitting to state that it is always indicated to answer a clinical 
question. The question is formulated by the transplant physicians with the knowledge of the 
patient’s clinical scenario, the results of relevant laboratory and imaging studies, and the 
response to any therapeutic measures already instituted to remedy the problem. The 
established indications for performing renal allograft biopsies are shown in Table 1.  
 
1. Delayed graft function (DGF) if worsening is seen in the renogram or DGF lasts longer 
than 2-3 weeks. 
2. Graft function lower than expected based on donor characteristics. 
3. A sudden rise in serum creatinine attributable to kidney disease.  
4. A progressive increase in creatinine levels (>20% from creatinine nadir). 
5. Proteinuria > 1 g. 
6. Urine sediment changes without apparent urological causes. 
7. Prior to changes in immunosuppressive treatment. 
Table 1. Established indications of renal allograft biopsies.  
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As is obvious from the table, renal allograft biopsy is indicated in both the acute and late 
dysfunction of the allograft as well as the investigation of recurrent/de novo glomerular 
disease. The causes of allograft dysfunction vary depending on the post-transplant duration, 
living vs. cadaveric source of organ, type of immunosuppression, underlying or primary 
disease, etc (Kazi & Mubarak, 2012). It is estimated that 30-50% of allografts develop 
dysfunction during the early period (John & Herzenberg, 2010). An accurate diagnosis of these 
is essential for the optimal management of the patients, as each of the major causes of renal 
allograft dysfunction requires different therapeutic approach (Colvin,1996; Gaber, 1998).   
3. Types of renal allograft biopsies 
Three important types of allograft biopsies are regularly and widely used in clinical 
transplant practice. These include; implantation biopsies, indication biopsies, and protocol 
biopsies. Each of these types of biopsy plays an important role in the optimal management 
of transplant patients if properly procured and interpreted (Racusen et al., 1999).  
3.1 Implantation biopsy, donor biopsy 
This is usually done after the allograft is anastomosed to the recipient’s vessels, but before 
the clamp is removed. The Banff scheme recommends its routine use all over the world. It 
provides baseline information on the status of the donor organ and helps in the 
interpretation of subsequent dysfunctional renal allograft biopsies. Individual zero time 
biopsies have been shown to correlate with the graft outcome.  
3.2 Indication biopsy 
3.2.1 Dysfunctional allograft biopsy 
These are the most common form of biopsies that are performed on the allograft and most 
challenging in their interpretation. These biopsies are most commonly performed during early 
post transplant period and their frequency decreases as the post transplant duration increases. 
The Banff schema has detailed guidelines on the processing and interpretation of morphological 
changes on renal allograft biopsies, which are periodically updated and revised.  
3.2.2 Allograft biopsy for proteinuria 
Although, majority of indication biopsies are done for a rise in serum creatinine, a 
significant proportion of biopsies are also performed for the investigation of proteinuria. 
The proportion of these biopsies increases as the post transplantation duration increases. 
Their optimal evaluation requires an approach similar to that used for native renal biopsies 
for the investigation of glomerular diseases, i.e., the use of immunoflourescence (IF), and 
electron microscopy (EM) in addition to light microscopy (LM).  
3.2.3 Protocol biopsies 
These are the renal allograft biopsies which are performed at pre-determined intervals after 
transplantation in normal functioning allografts. These biopsies have provided marked 
insights into the subclinical processes affecting the graft with implications for the long term 
graft outcome (Choi et al. 2005; Furness et al., 2003; Jain et al., 2000; Rush et al., 1998; Serón 
et al., 1997). Indeed, the concept of Banff classification of renal allograft pathology 
originated from the experience with the use of, and the publication of studies related to, 
protocol biopsies. However, these biopsies have been done at only a few centers in the 
world and are not universal.  
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4. Causes of renal allograft dysfunction 
The causes of renal allograft dysfunction can be conveniently divided into two categories 
depending on the time after transplantation; early and delayed, and generally follow the 
same pattern of etiologic factors as observed in native kidneys; pre-renal, renal, and post-
renal types. The causes of renal allograft dysfunction according to time after transplantation 
are shown in table 2.  
Acute or subacute renal allograft dysfunction generally manifests in the form of a sudden 
rise of serum creatinine. It is quite common and occurs in roughly half of all patients with 
kidney transplants. In the immediate post-transplant period, ischemic injury is the major 
cause, but acute rejection may occur during this period, especially acute antibody-mediated 
rejection (ABMR) in pre-sensitized recipients. However, majority of acute rejections 
manifest after one week. Over the first month, the risk of rejection is high and it gradually 
decreases over the ensuing few months. Acute rejection is rare after six months of 
transplantation. In contrast, acute ischemic injury can continue to occur at any time. Drug 
toxicity caused by calcineurin inhibitors (CNI) can occur at any time after transplantation 
and should always be in the differential diagnosis. Rarely, thrombotic microangiopathy 
(TMA) may occur, mainly caused by CNI toxicity, but has many other causes (Bergstrand et 
al., 1985: Pascual et al., 1999).  
 
Acute (0-6 months after transplant)
Acute cellular rejection 
Acute humoral rejection 
Acute calcineurin inhibitor toxicity 
Acute pyelonephritis 
Acute ischaemic injury 
 
Chronic (>6 months after transplant) 
Chronic cellular rejection 
Chronic humoral rejection 
Chronic calcineurin inhibitor toxicity 
Hypertension 
Chronic obstruction/reflux 
Chronic pyelonephritis 
Polyomavirus nephropathy 
Glomerular disease 
      Recurrent 
      De novo 
Graft ageing, including: 
       Donor-related changes 
       Progression of perioperative injury 
Post-transplant lymphoproliferative disorder 
Interstitial fibrosis / tubular atrophy, not otherwise specified 
Table 2. Causes of renal allograft dysfunction categorized according to time after 
transplantation.  
Late or chronic allograft dysfunction is usually labeled when graft dysfunction develops 
after six months of transplantation, and generally presents with a slowly rising serum 
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creatinine. It is often also accompanied by low grade proteinuria and hypertension as the 
post transplant duration increases. This chronic allograft loss occurs at a relatively constant 
rate of 2-4% per year and is the major cause of graft failure throughout the world. It is 
caused by a multitude of causes; both the allo-immune and the non-immune causes 
contribute to this process. Chronic CNI toxicity and hypertension are among the major 
etiologic factors leading to chronic graft loss. In addition, chronic obstruction, reflux, and 
hyperlipidemia are also contributing factors. As post transplant duration increases, the risk 
of recurrence of original renal disease or de novo occurrence of the same also increases. 
More recently, chronic allo-immune injury has been identified as a major cause of chronic 
graft loss. An acute rise in serum creatinine may occur during late post transplant period, 
and in most instances is caused by stopping the drugs by the patients. Similarly, a 
chronically failing allograft may show an apparent acute rise in serum creatinine, resulting 
from diminished functional reserve, and precipitated by some acute insult (John & 
Herzenberg, 2010).  
It is worth reiterating that the causes of renal allograft dysfunction vary depending on  
the induction protocol, maintenance immunosuppression, living vs. cadaveric organ source, 
and many other factors (D’Alessandro et al., 1995; Farnsworth et al., 1984; Matas et al.,  
2001; Mihatsch et al., 1985; Mishra et al., 2004; Ratnakar et al., 2002; Rizvi et al., 2011; Verma 
et al., 2007).  
5. Procurement of renal allograft biopsy 
Renal allograft biopsy procurement should follow the same methodology, as the native 
renal biopsy, discussed previously in chapter 1, especially, if ABMR is suspected or 
proteinuria is the clinical indication. The timing of obtaining biopsy is also important, 
especially for dysfunctional graft biopsies. Ideally, the biopsy should be obtained before any 
attempt at treatment of the suspected rejection process. It should be planned as an elective 
procedure, and a technician from the histopathology department should be present in the 
biopsy suite to examine the removed tissue under the dissection microscope for the 
adequacy of the tissue removed and for apportioning the removed tissue for 
immunoflourescence (IF) and EM study, if the later are required. This allows fulfillment of 
adequacy criteria for the proper histopathological evaluation of the biopsy material and 
complete pathologic evaluation including IF study for complement fragment C4d and renal 
panel IF. Two cores of renal graft tissue including both cortex and medulla should be 
obtained. The sensitivity of rejection diagnosis increases with increasing number of cores. 
The rejection process can be patchy and can be missed if only a single core is obtained. The 
sensitivity for rejection diagnosis is estimated to be around 90% with one core, and reaches 
99% if two cores of renal cortex are obtained. The sensitivity for rejection diagnosis varies 
from 75 to 80% if medulla alone is received. The specificity of diagnosis of rejection in the 
medullary tissue is even lower, as other causes of graft dysfunction such as infection, 
obstruction, or drug hypersensitivity may present with infiltrates and even tubulitis in the 
medulla (John & Herzenberg, 2010). 
6. Preparation of the biopsy for evaluation 
After the adequacy criteria are fulfilled, the graft biopsy material should be prepared with 
great care and dexterity. The biopsy should be processed and prepared according to the 
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guidelines for allograft biopsy handling by the most experienced technologists. The 
quality of biopsy material available for pathologic study is of utmost importance in the 
correct interpretation of the abnormalities in the tissue (Serón et al., 2008). Many centers 
process the biopsy by urgent methods, including microwave oven method (John & 
Herzenberg, 2010). We also process the allograft biopsies by the rapid method using auto-
processor and report the biopsies on the same day. The quality of reagents is also very 
important. According to Banff schema, it is recommended to prepare at least seven slides, 
with multiple sections mounted on each slide. Three of these should be stained with 
hematoxylin and eosin (H&E), three with periodic acid-Schiff reagent (PAS), and one with 
a Masson’s trichrome stain. The PAS and/or silver stains are very useful in delineating 
tubular basement membranes (TBMs) and in defining the severity of tubulitis, and for 
evaluating glomerulitis. The PAS stain is also useful in the identification of arteriolar 
hyalinosis (ah) and tubular atrophy and their semi-quantitative scoring. Trichrome stains 
help in assessing the chronic sclerosing changes in the interstitium and in the arterial 
intima. Banff schema recommends cutting tissue sections at a thickness of 3 to 4 microns 
for an accurate semiquantitative assessment of the morphological lesions in the biopsy 
sections (Racusen et al., 1999).  
7. Pathologic evaluation of allograft biopsy 
The accurate pathologic evaluation of renal allograft biopsy requires a well trained renal 
pathologist with a thorough knowledge of renal transplant pathology, and also of renal 
and transplant medicine in order to correlate the morphologic abnormalities with the 
detailed clinical information. The importance of correlation of morphological findings on 
the renal allograft biopsy with clinical data and a close liaison between the nephrologists 
and pathologists cannot be overemphasized and is self-explanatory. However, the biopsy 
should be examined by the pathologist initially, without reference to the available clinical 
information and a morphological diagnosis formulated. This morphological diagnosis 
should be an objective and unbiased record of all abnormalities seen under the 
microscope. An attempt should then be made to correlate the clinical details provided 
with the morphological changes and preferably following discussion with the clinicians. 
A final diagnosis is then made and any treatment available, given. Further, in an ideal 
situation a follow up on the patient’s progress is also communicated to the pathologist so 
that the predictions made from the biopsy can be confirmed or corrected if possible. Renal 
allograft biopsy interpretation is therefore developed out of a discussion between a 
clinician and the renal pathologist and is a learning process for both based on the patient's 
clinical course. In this context, it is worth emphasizing that transplant pathology is the 
youngest discipline of surgical pathology and is continuously evolving rapidly (John & 
Herzenberg, 2010).  
8. Diagnosis of acute graft dysfunction 
Acute graft dysfunction may be caused by acute ischemic injury, acute rejection, or drug 
toxicity. Rare causes include; infections, surgical complications, vascular complications, or 
obstruction. Acute ischemic injury with delayed graft function (DGF) is more common in 
the cadaveric setting and is recognized by degenerative and regenerative changes in the 
tubular epithelium. 
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Renal graft biopsy is the gold standard test to identify many of these lesions. However, it is 
invasive, and not without risks (Vidhun et al., 2003; Wilckzek, 1990). Renal allograft biopsies 
are of three major types according to their indications: time zero biopsies or implantation 
biopsies; dysfunctional graft biopsies; and protocol biopsies. Among these, the second 
category is obviously the most common type in most of the centers around the world. Many 
centers do not perform routine implantation or protocol biopsies.   
8.1 Diagnosis of acute rejection 
Renal allograft biopsy is the gold standard procedure for the diagnosis of acute rejection. 
Acute rejection was traditionally classified on the basis of rapidity and severity of the 
process, as hyperacute, acclerated acute, and acute rejection. Banff classification tried to 
classify the rejection on the basis of pathological and pathogenetic mechanisms with 
considerable refinements in the classification over the past 20 years (Solez et al., 1993; 
Racusen et al., 1999; Racusen et al., 2003; Solez et al., 2007; Solez et al., 2008). More 
recently, the Banff classification has categorized acute rejection on pathogenetic 
mechanisms, as acute ABMR and acute T cell mediated rejection (TCMR). Each of these 
types of rejection has unique morphological, immunohistochemical, and clinical features 
and different responses to therapy. Acute TCMR is diagnosed on the concurrent 
fulfillment of two key thresholds: significant interstitial lymphocytic infiltration (i2) 
associated with significant tubulitis (t2). If only one of these features is present, the 
diagnosis is made of borderline rejection. The borderline category exists only in type I or 
TCMR. Once a diagnosis of acute TCMR is made, its severity is assessed mainly on the 
basis of severity of tubulitis as Type IA and IB. Acute TCMR may also manifest as varying 
degrees of arterial inflammation and necrosis. It most often causes intimal arteritis, but 
occasional cases may manifest as V3 lesion. Often the vascular involvement is 
accompanied by tubulo-interstitial inflammation.  
8.2 Mechanisms of rejection  
Rejection is a complex and somewhat redundant response of the specific and innate immune 
systems to the allograft tissue. The major targets of this response are the major 
histocompatibility complex (MHC) antigens, which are known as human leukocyte antigens 
(HLAs) in humans. The HLA genes on the short arm of chromosome 6 encode two 
structurally distinct classes of cell-surface antigens, known as class I (HLA-A, -B, and -C) 
and class II (-DR, -DQ, -DP). The T lymphocytes recognize allograft antigens by one of two 
mechanisms; direct and indirect allorecognition. In the direct pathway, T cells recognize 
intact allogenic MHC molecules on the surface of allogenic donor cells. The T-cell response 
that results in early acute TCMR is caused mainly by direct allorecognition. In the indirect 
pathway, T cells recognize processed alloantigens in the context of self antigen presenting 
cells (APCs). Indirect presentation may be important in maintaining and amplifying the 
rejection response, especially in chronic rejection. 
In both pathways, T lymphocytes recognize foreign antigen only when the antigen is 
associated with HLA molecules on the surface of APCs. Helper T lymphocytes (CD4) are 
activated and they proliferate, differentiate, and secrete a variety of cytokines. These 
cytokines increase expression of HLA class II antigens on the allograft tissues, stimulate B 
lymphocytes to produce antibodies against the graft antigens, and help cytotoxic T cells 
(CD8), macrophages, and natural killer cells to develop effective specific and innate 
immunity against the graft (Nankivell & Alexander, 2010). 
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8.3 Semiquantitative assessment of histological changes – The mainstay of Banff 
schema  
The semiquantitative scoring of the acute and chronic structural changes in different 
compartments of the graft parenchyma forms the mainstay for the Banff classification of 
renal allograft pathology (Solez et al., 1993; Racusen et al., 1999; Racusen et al., 2003; Solez et 
al., 2007; Solez et al., 2008). Altogether, five categories of acute and four of chronic changes 
are assessed. These are given in table 3. 
 
 Acute changes: 
 
g 0, 1, 2, 3 No, mild, moderate, severe glomerulitis (g3 = mononuclear cells in 
 capillaries of all or nearly all glomeruli with endothelial enlargement 
 and luminal occlusion) 
i 0, 1, 2, 3 No, mild, moderate, severe interstitial mononuclear cell infiltration  
 (in rejection edema & lymphocyte activation usually 
  accompany mononuclear cell infiltration: i3 = >50% pf parenchyma 
 inflamed)  
t 0, 1, 2, 3 No, mild, moderate, severe tubulitis (t3 = >10 mononuclear cell per 
 tubule or per 10 tubular cells in several tubules) 
v 0, 1, 2, 3 No, mild, moderate, severe intimal arteritis (assessed in most 
  involved vessel) (v3 = severe intimal arteritis and / or 
  transmural arteritis and / or hemorrhage and recent 
  infarction) 
ah 0, 1, 2, 3 No, mild, moderate, severe nodular hyaline afferent arteriolar  
  thickening suggestive of cyclosporine toxicity (ah3 = severe  PAS- 
  positive thickening in many arterioles) 
 
Chronic changes: 
 
cg 0, 1, 2, 3 No, mild, moderate, severe chronic transplant glomerulopathy 
  (% glomeruli). 
ci 0, 1, 2, 3 No, mild, moderate, severe interstitial fibrosis, often with mononuclear 
  cell inflammation (% total interstitial area). 
ct 0, 1, 2, 3 No, mild, moderate, severe tubular atrophy and loss 
  (% tubular area). 
cv 0, 1, 2, 3 No, mild, moderate, severe fibrous intimal thickening often with 
  elastica fragmentation (cv3 indicates occlusion( (cg and cv lesions  
  suggest the presence of chronic rejection) (assessed in most damaged  
  vessels). 
Table 3. Semiquantitative scoring of acute and chronic changes in different compartments of 
renal graft parenchyma.  
The focus of acute rejection diagnosis in Banff schema is on the tubulitis and intimal 
arteritis. However, it is worth emphasizing that with the exception of arteritis, there is no 
single specific feature of rejection. The diagnosis of rejection depends on the concurrence of 
interstitial inflammation of at least i2 (>25% to <50% of the unscarred parenchyma) and a 
tubulitis of grade t2 (4 -10 lymphocytes invading the tubule), as shown in Figures 1 and 2. 
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Fig. 1. Low-power view showing almost diffuse, dense, lymphocytic infiltrate in the 
interstitium. This is highly suggestive of acute T cell mediated rejection. (H&E, ×100). 
The tubulitis grading is carried out on the most severely involved tubule. Most difficulty is 
encountered in the diagnosis of Type I acute cellular rejection, ie., the tubulo-interstitial 
type, especially during very early stages of the process. The process starts and builds 
gradually with interstitial accumulation of progressively increasing numbers of 
inflammatory cells which later invade and attack the tubules. Thus if the biopsy is done at 
very early stage, tubulitis may not be found (Kazi et al., 1998). The rejection also begins as a 
patchy process, which in later stages becomes diffuse. The clearly defined threshold of 
rejection diagnosis, especially interstitial inflammation and tubulitis, has helped in 
improving the interobserver reproducibility of diagnosis (Furness et al., 1997; Furness et al., 
1999). The rationale behind this threshold setting is that some inflammatory changes are to 
be expected in any allograft, but do not signal rejection. At the same time, this has resulted 
in lower sensitivity of diagnosis of very early acute TCMR. For this reason, various 
investigators have tried alternative approaches for increasing the sensitivity of diagnosis of 
early acute TCMR. One such approach involves the use of a computer program, known as 
Baysian Belief Network (BBN) to record and analyze multiple biopsy features to diagnose 
more accurately the cases of early acute rejection. In one study involving 21 difficult cases of 
early acute rejection, the use of computer program resulted in higher correct diagnoses than 
any of the pathologists using the Banff criteria (Furness et al., 1999; Kazi et al., 1998). 
Moreover, there are interinstitutional differences in the quality and quantity of 
inflammatory infiltrates of rejection (Furness & Taub, 2001; Furness et al., 2003; Kazi et al., 
1999). In spite of these limitations, Banff schema has become the international benchmark for 
the pathologic interpretation of renal allograft biopsies.  
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Fig. 2. Medium-power view showing almost diffuse, dense, lymphocytic infiltrate in the 
interstitium associated with foci of significant tubulitis (t2). This is highly suggestive of 
acute T cell mediated rejection. (H&E, ×200). 
 
 
Fig. 3. Medium-power view showing part of wall of artery with focal intimal arteritis 
consistent with acute vascular rejection: Banff category, IIA. There is also dense lymphocytic 
infiltrate in the surrounding interstitium. (PAS stain, ×200).  
www.intechopen.com
 
Topics in Renal Biopsy and Pathology 
 
168 
The diagnosis of acute vascular rejection (AVR) is most often straight forward. Detection of 
even a single lymphocyte in the arterial intima (intimal arteritis) is sufficient to diagnose a case 
as AVR. The severity of rejection is also graded on the basis of V scores. AVR may be a 
manifestation of TCMR or antibody-mediated rejection (ABMR). The later mechanism of 
rejection most often results in V3 lesions, while the former pathway causes V1 and V2 lesions 
(Figures 3 to 7).  
Significant tubulointerstitial inflammation and vasculitis may also be a manifestation of 
recurrent or de novo development of renal disease in the allograft. A good pretransplant 
clinical history is highly valuable in resolving this differential, the occurrence of which 
increases with increased post-transplant duration.  
 
 
Fig. 4. High-power view showing numerous lymphocytes invading the arterial intima. 
Many red blood cells are also seen in the intima. (H&E stain, ×400).  
8.4 Antibody-mediated rejection (ABMR) 
Recently, more attention is focused on antibody mediated rejection (ABMR) as a common 
cause of graft loss, and it is increasingly being recognized as an important cause of both 
acute and chronic renal allograft injury (Mauiyyedi et al., 2001;Mauiyyedi et al., 2002). This 
has been made possible with the discovery and the widespread use of C4d as a marker of 
ABMR. The detailed diagnostic criteria and classification of ABMR have been developed 
during recent updates of the Banff classification. A category of C4d negative ABMR has also 
been included in Banff 07 classification.  
The definite diagnosis of ABMR requires fulfillment of three criteria; the histological 
evidence of graft injury, the immunohistochemical evidence of C4d positivity, and the 
presence of donor specific antibodies (DSA). If only two of these criteria are present, the case 
is labeled as presumptive ABMR. The pathological changes of ABMR may coexist with other 
categories of alloimmune or non-immune injuries of the graft (Racusen et al., 1999; Racusen 
et al., 2003; Solez et al., 2007; Solez et al., 2008).  
www.intechopen.com
 
Pathology of Renal Transplantation 
 
169 
 
Fig. 5. Medium-power view showing severe/circumferential intimal arteritis, consistent 
with acute vascular rejection; Banff category, IIA. (H&E, ×200).  
 
 
Fig. 6. Medium-power view showing two small arteries showing transmural arteritis along 
with a small area of fibrinoid necrosis in one of the arteries. This is consistent with V3 lesion 
and is categorized as acute vascular rejection; Banff category, III. Although, this 
morphological change may be seen in acute cellular rejection, this lesion is typically seen in 
cases of antibody mediated rejection (H&E, ×200). 
www.intechopen.com
 
Topics in Renal Biopsy and Pathology 
 
170 
A variety of morphological changes have been described, which, although, not entirely 
specific, are found more commonly in cases of ABMR. These changes include; 
polymorphonuclear glomerulitis, peritubular capillaritis, fibrin thrombi in glomerular 
capillaries, and fibrinoid necrosis of arteries. More recent Banff updates have formulated 
criteria for scoring the peritubular capillaritis and C4d positivity. These are undergoing 
clinical validation studies in many transplant centers in the world (Racusen et al., 1999; 
Racusen et al., 2003; Solez et al., 2007; Solez et al., 2008).  
  
 
Fig. 7. Medium-power view showing fibrinoid necrosis of the wall of one small artery, 
characteristic of antibody mediated rejection. The wall of adjacent large artery shows intimal 
arteritis. (H&E, ×200). 
9. Pathological changes not related to allo-immune mechanisms 
9.1 Calcineurin inhibitor (CNI) drug toxicity  
Calcineurin inhibitors (CNIs) including cyclosporine (CsA) and tacrolimus form the 
mainstay of maintenance immunosuppression. The discovery of CsA in 1979 has 
revolutionized the iatrogenic immunosuppressive protocols and the overall success rate of 
solid organ transplantation. However, the drugs are also potentially nephrotoxic, causing 
both acute and chronic nephrotoxicity. Acute CNI toxicity is one of the important causes of 
acute graft dysfunction. It also frequently poses differential diagnostic problems with acute 
TCMR. Toxic effects of CsA have been studied in detail, however, the toxicity profile of 
tacrolimus is still being defined. Both the mechanism of action and the toxicity profile of the 
two drugs also shows overlapping features (Figures 8 to 10). Acute tubular injury (ATI) is 
the most common lesion, accompanied by isometric vacuolization of tubular epithelial cell 
cytoplasm. This change is observed in both the proximal and distal convoluted tubules, and 
focal coalescence of vacuoles may yield larger vacuoles. Both the drugs are also associated 
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with microvascular toxicity characterized by damage to glomerular capillaries and renal 
arterioles. Acute arteriolar damage manifests in a variety of ways: there may be endothelial 
cell swelling, mucinous intimal thickening, nodular hyalinosis, and focal medial necrosis. 
Marked vacuolization of media of arterioles is also frequently observed (Figure 9). Sometimes, 
CNI toxicity manifests itself in the form of thrombotic microangiopathy (TMA). Chronic CNI 
toxicity results in nodular arteriolar hyalinosis, characterized by hyaline, eosinophilic deposits 
encroaching onto the media. These deposits consist of fibrin, IgM, C3, and C1q. This nodular 
hyalinosis differs from the circumferential arteriolar hyalinosis limited to the intima, and 
found in aging, hypertension, and diabetes mellitus. We have observed nodular arteriolar 
hyalinosis in CNI toxicity as early as one week after transplantation (unpublished data). Drug 
induced vasculopathy leads to ischemic injury accentuated in the medullary rays, leading to 
striped or diffuse interstitial fibrosis (Myers et al., 1984).  
 
 
Fig. 8. Medium-power view showing part of a glomerulus with an arteriole, showing 
nodular hyalinosis. The hyaline is replacing the media and adventitia. This is highly 
suggestive of cyclosporine toxicity. (PAS, ×200). 
9.2 Infections  
The iatrogenic immunosuppression induced in renal transplant patients predisposes these 
patients to a variety of infections. The etiologic agents and the site of infections varies 
depending on a number of factors. Among the different infective agents affecting renal 
transplant recipients, bacterial, fungal, protozoal, and viral infections are common. Urinary 
tract infections are common in renal transplant patients in the early post-transplant period. 
The infective agents may affect the allograft or the native organs of the recipient. Bacterial 
infections may involve the graft and may be diagnosed on renal allograft biopsy. Bacterial  
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Fig. 9. Medium-power view showing three arterioles with marked vacuolization of medial 
muscle fibers. This change is also suggestive of cyclosporine toxicity. (PAS, ×200). 
infections result in a mixed inflammatory cell infiltrate in the interstitium with a 
predominance of neutrophils, associated with tubular microabscesses (Figures 11 and 12). 
The infiltrate is usually localized in the medulla but may be found in the cortex. Sometimes, 
the infection may not be picked up on urine culture (Imtiaz et al., 2000; Oguz et al., 2002). 
Among the viral infections affecting the graft, CMV and polyoma viruses are of paramount 
importance (Nickeleit et al., 1999).  
9.3 Posttransplant Lymphoproliferative Disorder (PTLD) 
Although rare, this disorder is an important differential diagnosis with acute cellular 
rejection, especially as the posttransplant duration increases. An early diagnosis of this 
complication is necessary for its successful management. Although, typically the disorder 
occurs many months to years after transplantation, there are many examples of its 
occurrence during early posttransplant period.  
On light microscopy, PTLD is characterized by a monomorphic or polymorphic 
lymphocytic infiltrate containing plasma cells, many of which are atypical. There is 
typically a diffuse interstitial infiltrate without associated tubulitis or arteritis, the later 
features help in its differential diagnosis from rejection. Occasionally, the two processes 
may be concurrent. Immunophenotyping of lymphocytes helps in the definite diagnosis 
of this concurrence.  
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Fig. 10. High-power vies showing prominent isometric vacuolization of tubular epithelial 
cells in two tubules in the center of the field. Although, no specific, this is highly suggestive 
of cyclosporine toxicity. (H&E, ×400). 
 
 
Fig. 11. Medium-power view showing dense, mixed inflammatory cell infiltrate with 
predominnat neutrophils. This is strongly suggestive of infection.  (H&E, ×200). 
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Fig. 12. High-power view showing accumulation of polymorphonuclear neutrophils in the 
tubular lumina, so called tubular microabscesses. These are  highly suggestive of infection.  
(H&E, ×400). 
9.4 Acute Tubular Necrosis (ATN) 
Acute tubular injury (ATI) or ATN is a common finding in renal biopsies from transplanted 
kidneys, especially in the cadaveric setting. It is the main cause of primary nonfunction of 
the allograft in this setting. ATI results from a multitude of causes and situations, including 
in situ injury in the donor; ischemia during organ harvesting, storage, or transportation of 
the organ; and ischemic injury incurred perioperatively in the recipient. The morphological 
picture is similar to that seen in the native kidneys and spans the whole spectrum from mild 
injury, which is difficult to identify, to severe flattening and loss of tubular epithelium from 
the tubular basement membrane. These degenerative changes in the tubular epithelial cells 
are accompanied by signs of regeneration, including mitoses. There may be accompanying 
interstitial edema, and mild mixed inflammatory cell infiltration. Tubulitis is typically 
absent or only trivial. Other changes include tubular cell vacuolization and blebbing, and 
tubular dilatation reflecting downstream tubular obstruction. There are also deposits of 
calcium salts in tubular lumina in the form of dystrophic calcification.  
There is a poor correlation between the morphological changes of ATN and the allograft 
function. Although, the morphological lesions of ATI or ATN in the transplanted kidneys 
are similar to those of native kidneys, some authors have noted a few differences in the 
morphological profile.  
9.5 Acute Tubulointerstitial Nephritis (ATIN) 
Non-immune related ATIN may occur in the transplanted kidneys and may be very difficult 
to distinguish from the tubulointerstitial rejection. The disorder may result from a variety of 
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insults to the transplanted kidneys, such as infection, drug hypersensitivity, viral infection, 
etc. A predominance of neutrophils in the mixed inflammatory cell infiltrate in the 
interstitium, especially if associated with tubular microabscesses or leucocyte casts favor the 
possibility of infection. A predominance of eosinophils raises the possibility of drug 
hypersensitivity. Viral infections are accompanied by appropriate viral cytopathic effects in 
addition to the infiltrate. It may be reiterated here that neutrophils and eosinophils may also 
be seen in rejection, and sometimes the above lesions are superimposed on underlying 
rejection reaction.  
10. Diagnosis of chronic allograft dysfunction 
As is evident in table 2, the causes of late allograft dysfunction are more varied that those of 
acute allograft dysfunction. The late graft dysfunction may manifest as an acute rise in 
serum creatinine or a slowly increasing serum creatinine, and the causes vary accordingly. 
An advanced failing allograft may show an apparent acute decline of graft function due to 
diminished renal reserve, as in native kidneys. Renal allograft biopsy is essential to diagnose 
the causes of late allograft dysfunction.  
In the past, all cases of chronic allograft dysfunction were labeled as “chronic allograft 
nephropathy” by the pathologists, a “paper wastebasket” for all forms of chronic allograft 
damage (Cornell & Colvin, 2005; Ivanyi et al., 2001; Nankivell et al., 2003). This was 
mainly because the morphological features of various diseases were not clearly defined, 
as well as, the loss of features of primary pathology in advanced stages of sclerosing 
process. The main morphological changes of specific causes of chronic allograft 
dysfunction are shown in table 4. 
The diagnosis of interstitial fibrosis/tubular atrophy, not otherwise specified, is reserved 
only for those cases, which show no evidence of specific causes after a detailed and 
meticulous investigation of the allograft biopsy by morphology, immunohistochemistry, 
electron microscopy, and molecular genetic methods.  
11. Recurrent and de novo renal diseases 
There are many renal diseases, especially glomerular diseases, which can recur in the 
transplanted kidneys after a variable period of time (Hariharan, 2000). Currently, 
glomerular diseases account for approximately 10-20% of cases of ESRD undergoing 
transplantation, and overall approximately 20% of these patients experience recurrence. The 
same disease can also occur as de novo disease in the transplanted kidneys. Disease 
characteristics of the recurrent disease are similar to those of the original disease, but are 
usually mild in nature. This may be due in part to the use of immunosuppressive agents in 
the transplant patients. De novo diseases generally occur later than the recurrent diseases. 
Almost all diseases that occur in the native kidneys can occur de novo in transplant kidneys. 
However, the two most common diseases are membranous glomerulonephritis and focal 
segmental glomerulosclerosis. The work up of renal allograft biopsies in cases suspicious for 
recurrent or de novo glomerulopathies should follow the approach used in native renal 
biopsy investigation.  
One important non-glomerular disease that frequently recurs in transplanted kidneys is the 
primary hyperoxaluria, if kidney transplantation is carried out without concomitant liver 
transplantation.  
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Chronic hypertension:  fibrous thickening of the arterial intima with reduplication of 
elastic lamina, and arteriolar hyalinosis. 
Chronic calcineurin inhibitor toxicity: nodular peripheral arteriolar hyalinosis, and 
striped interstitial fibrosis 
Chronic obstruction: prominent tubular dilation, and ruptured tubules with extravasated 
casts 
Chronic pyelonephritis: chronic interstitial inflammation and fibrosis, out of proportion 
to vascular or glomerular changes, in the context of clinical history of recurrent urinary 
tract infections 
Polyomavirus nephropathy: tubular epithelial viral infection evidenced by typical viral 
inclusions on H&E stain, or positive staining for SV40-large T antigen 
De novo/recurrent renal diseases:  morphological features of respective diseases 
Table 4. The morphological features of specific causes of chronic allograft dysfunction, other 
than chronic allo-immune causes.  
12. Conclusion 
In conclusion, renal transplant pathology is a complex and rapidly evolving field, in which 
significant improvements have taken place in recent years in both the characterization and 
categorization of allo-immune mechanisms of injury.  More refinement is expected to take 
place in near future with the inclusion of molecular genetic and image analysis techniques 
into the Banff classification. 
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